GlassScriptPhysician profile
Seymour Katz
NPI 1255337424
$3,528.17
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,176 · 2020: $299 · 2021: $56.92 · 2022: $927 · 2023: $13.65 · 2024: $56.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $794.14 | 2019-2024 | |
| Pfizer INC. | $510.86 | 2019-2022 | |
| Janssen Biotech, INC. | $452.29 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $323.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $256.61 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.34 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $200.99 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $162.80 | 2019-2022 | |
| Celgene Corporation | $119.47 | 2022 | |
| Ferring Pharmaceuticals INC. | $116.19 | 2019-2022 | |
| Ucb, INC. | $82.52 | 2019-2020 | |
| Redhill Biopharma INC. | $47.85 | 2022 | |
| Braintree Laboratories, INC. | $44.37 | 2019-2022 | |
| Ardelyx, INC. | $41.59 | 2022 | |
| Ironwood Pharmaceuticals, INC | $31.74 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $30.02 | 2022 | |
| Phathom Pharmaceuticals, INC. | $27.58 | 2024 | Voquezna |
| Concordia Pharmaceuticals INC. | $18.99 | 2019 | |
| Genzyme Corporation | $18.35 | 2022 | |
| Endo Pharmaceuticals INC. | $13.53 | 2019 | |
| Evoke Pharma, INC. | $13.23 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seymour Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.